Please assess the completion status of the following clinical trial:

Trial Title: 5-Alpha Reductase and Anabolic Effects of Testosterone

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 60 years males~* Primary care at the Malcolm Randall VA Medical Center in Gainesville, Florida.~* Consenting subjects who have a morning (between 6:00 AM and 10:00 AM) serum total testosterone 300 ng/dL or bioavailable testosterone concentration 70 ng/dL and no exclusion criteria will be randomized to receive either testosterone or placebo.~Exclusion Criteria:~* Subjects with cognitive impairment will be identified by the Mini-Cog test and excluded. The Mini-Cog has high sensitivity and specificity for cognitive impairment, and is not affected by level of education.~* We will also exclude subjects with receptive aphasia, or a contraindication to testosterone replacement (i.e., history of or active prostate or breast cancer, severe benign prostatic hyperplasia as assessed by elevated American Urologic Association Symptom Index (AUASI) score \> 25), congestive heart failure (Class 3 or 4), sleep apnea syndrome, polycythemia (Hct \> 55%), or prostate specific antigen (PSA) \> 2.6 ng/mL) will be excluded.~* Obese subjects (BMI \> 35) will also be excluded.~* Subjects currently receiving testosterone supplementation or subjects who have an allergy to testosterone will also be excluded.~* Subjects previously receiving testosterone replacement therapy must be off such medication for at least four weeks.

- Gender: MALE
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): testosterone enanthate
- Arm 2 (Type: EXPERIMENTAL): finasteride
- Arm 3 (Type: EXPERIMENTAL): testosterone enanthate + finasteride
- Arm 4 (Type: PLACEBO_COMPARATOR): placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).